TABLE 2.
Baseline bacterial characteristics of the primary cohort
| Characteristic, n (%)e | 30-day mortality |
All patients (n = 49) |
|
|---|---|---|---|
| No (n = 33) |
Yes (n = 16) |
||
| Sequence Type | |||
| 258 | 24 (73) | 12 (75) | 36 (73) |
| 11 | 0 0 | 2 (13) | 2 (4) |
| 307 | 2 (6) | 0 | 2 (4) |
| Othera | 7 (21) | 2 (13) | 9 (18) |
| wzi capsule type | |||
| 154 | 13 (39) | 8 (50) | 21 (43) |
| 29 | 12 (36) | 5 (31) | 17 (35) |
| 173 | 2 (6) | 0 | 2 (4) |
| 27 | 0 | 2 (13) | 2 (4) |
| Other | 6 (18) | 1 (6) | 7 (14) |
| Carbapenemaseb | |||
| blaKPC-2 | 15 (45) | 8 (50) | 23 (47) |
| blaKPC-3 | 16 (50) | 8 (50) | 24 (50) |
| blaOXA-232 | 2 (6) | 1 (6) | 3 (6) |
| ESBL | |||
| blaSHV-12 | 15 (45) | 10 (63) | 25 (51) |
| blaCTX-Mc | 8 (24) | 2 (13) | 10 (20) |
| Antimicrobial nonsusceptibilityd | |||
| COL | 2/31 (6) | 1/15 (7) | 3/46 (7) |
| CAZ/AVI | 0/20 | 0/12 | 0/32 |
a
Includes ST16(1), ST231(1), ST2891(1), ST3631(1), ST37(1), ST418(1), ST45(1), ST76(1), ST985(1).
b
Isolates could carry multiple genes encoding β-lactamases.
c
Includes blaCTX-M-14 (1) and blaCTX-M-15 (9).
d
Includes only those isolates tested for susceptibilities.
e
ESBL, extended-spectrum β-lactamase; COL, colistin; CAZ/AVI, ceftazidime-avibactam.